Curanex Pharmaceuticals (CURX) Accounts Payables (2024 - 2025)
Curanex Pharmaceuticals' (CURX) quarterly Accounts Payables came in at $2426.0 in Q4 2025, down 51.48% YoY from $5000.0 in Q4 2024, and down 97.88% on a QoQ basis from $114489.0 in Q3 2025.
Curanex Pharmaceuticals (CURX) Accounts Payables (2024 - 2025) Analysis & Trends
Curanex Pharmaceuticals (CURX) has 2 years of Accounts Payables data on file, last reported at $2426.0 in Q4 2025.
- Quarterly Accounts Payables fell 51.48% year-over-year to $2426.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2426.0 (down 51.48% YoY) and the FY2025 annual result came in at $2426.0, down 51.48% from the prior year.
- Accounts Payables retreated to $2426.0 in Q4 2025, from $114489.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $114489.0 in Q3 2025 to a low of $269.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Curanex Pharmaceuticals | 6.02 Mn | 1.02 Mn | - | 2,426.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2,426.00 |
| Sep 30, 2025 | 114,489.00 |
| Jun 30, 2025 | 269.00 |
| Dec 31, 2024 | 5,000.00 |